Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.
The Indian drugmaker highlighted resilience in its domestic formulations business. This segment continued to deliver solid performance amid broader market conditions.
Indian pharmaceutical companies Dr Reddy's and Cipla reported weaker results for the June quarter due to falling profits in the US market. Their domestic operations performed better and provided some offset. Analysts lowered earnings estimates for future years as a result.
Ti AI ṣe iroyin
Corporate India posted robust revenue increases during the March 2026 quarter. However, rising input costs and a weaker rupee pressured operating margins across many companies.
Market expert Sunil Subramaniam has advised caution for investors amid geopolitical uncertainty and rising input costs. He highlighted consumer durables, capital goods and public sector banks as preferred sectors.
Ti AI ṣe iroyin
Dr Reddy's Laboratories expects a gradual recovery in the current fiscal year after a profit decline last year. Growth in India, Europe, and emerging markets is offsetting pressures in the US business. New product launches and margin improvements are set to support expansion.